The High Serum Monocyte Chemoattractant Protein-1 in Obesity is Influenced by High Parathyroid Hormone and Not Adiposity

Overview

Journal J Clin Endocrinol Metab

Publisher Oxford University Press

Specialty Endocrinology

Date 2011 Apr 22

PMID 21508136

Citations 16

Authors

D Sukumar

N C Partridge

X Wang

S A Shapses

Affiliations

Soon will be listed here.

Abstract

Context: Chronic high levels of PTH may be associated with up-regulation of proteases and cytokines. Monocyte chemoattractant protein-1 (MCP-1) is an inflammatory cytokine, produced predominantly by macrophages and endothelial cells, and is expressed in adipose tissue. More recently it has been shown that PTH administration increases MCP-1 expression in osteoblasts.

Objectives: Because both PTH and MCP-1 levels are higher in obesity, the goal was to determine whether the high MCP-1 occurs only in the presence of high serum PTH and is independent of adiposity and examine its relationship with bone mineral density (BMD) and turnover.

Design, Setting, And Participants: In this case-control clinical design, 111 eligible women were categorized into four groups: leaner women [body mass index (BMI) 23 ± 2 kg/m(2)] with normal or higher PTH and obese (BMI 44 ± 7 kg/m(2)) with normal or higher PTH.

Results: Serum MCP-1 levels were higher (P < 0.01) in the high (PTH = 74.9 ± 27.0 pg/ml, MCP-1 = 421.5 ± 157.0 pg/ml) compared with normal PTH (PTH = 32.5 ± 10.4 pg/ml, MCP-1 = 322.5 ± 97.8 pg/ml) group, independent of BMI. C-reactive protein and adiponectin were influenced only by BMI and not PTH. MCP-1 was positively associated with osteocalcin and propeptide of type 1 collagen in the leaner (r > 0.3, P < 0.05) but not the obese women and was not associated with BMD in either group.

Conclusions: Together these data suggest that MCP-1 is higher only in the presence of increased PTH and that adiposity alone cannot explain the higher MCP-1 levels in obesity.

Citing Articles

Bone Disease in Primary Hyperparathyroidism-Changes Occurring in Bone Metabolism and New Potential Treatment Strategies.

Iwanowska M, Kochman M, Szatko A, Zgliczynski W, Glinicki P Int J Mol Sci. 2024; 25(21).

PMID: 39519190 PMC: 11546563. DOI: 10.3390/ijms252111639.

The Role of Inflammatory Mediators in the Pathogenesis of Obesity.

Bakinowska E, Krompiewski M, Boboryko D, Kielbowski K, Pawlik A Nutrients. 2024; 16(17).

PMID: 39275140 PMC: 11396809. DOI: 10.3390/nu16172822.

Molecular and pathophysiological relationship between obesity and chronic inflammation in the manifestation of metabolic dysfunctions and their inflammation‑mediating treatment options (Review).

Varra F, Varras M, Varra V, Theodosis-Nobelos P Mol Med Rep. 2024; 29(6).

PMID: 38606791 PMC: 11025031. DOI: 10.3892/mmr.2024.13219.

Abaloparatide Has the Same Catabolic Effects on Bones of Mice When Infused as PTH (1-34).

Le Henaff C, Finnie B, Pacheco M, He Z, Johnson J, Partridge N JBMR Plus. 2023; 7(2):e10710.

PMID: 36751417 PMC: 9893269. DOI: 10.1002/jbm4.10710.

Parathyroid gland weight is associated with high density lipoprotein levels in patients with primary hyperparathyroidism.

Dayyeni A, Mahdi A, He Y, Trooskin S, Meng L, Wang X J Clin Transl Endocrinol. 2020; 19:100213.

PMID: 31890605 PMC: 6926342. DOI: 10.1016/j.jcte.2019.100213.

References

Kamycheva E, Sundsfjord J, Jorde R . Serum parathyroid hormone level is associated with body mass index. The 5th Tromsø study. Eur J Endocrinol. 2004; 151(2):167-72. DOI: 10.1530/eje.0.1510167. View

Rollins B . Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Mol Med Today. 1996; 2(5):198-204. DOI: 10.1016/1357-4310(96)88772-7. View

Arakelyan A, Petrkova J, Hermanova Z, Boyajyan A, Lukl J, Petrek M . Serum levels of the MCP-1 chemokine in patients with ischemic stroke and myocardial infarction. Mediators Inflamm. 2005; 2005(3):175-9. PMC: 1526470. DOI: 10.1155/MI.2005.175. View

Arunabh S, Pollack S, Yeh J, Aloia J . Body fat content and 25-hydroxyvitamin D levels in healthy women. J Clin Endocrinol Metab. 2003; 88(1):157-61. DOI: 10.1210/jc.2002-020978. View

Parikh S, Edelman M, Uwaifo G, Freedman R, Semega-Janneh M, Reynolds J . The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults. J Clin Endocrinol Metab. 2004; 89(3):1196-9. DOI: 10.1210/jc.2003-031398. View

Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C . Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes. 2005; 54(8):2277-86. DOI: 10.2337/diabetes.54.8.2277. View

Grey A, Mitnick M, Shapses S, Ellison A, Gundberg C, Insogna K . Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption--a clinical research center study. J Clin Endocrinol Metab. 1996; 81(10):3450-4. DOI: 10.1210/jcem.81.10.8855783. View

Wortsman J, Matsuoka L, Chen T, Lu Z, Holick M . Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2000; 72(3):690-3. DOI: 10.1093/ajcn/72.3.690. View

Andersen T, McNair P, Hyldstrup L, Nielsen T, Astrup A, TRANSBOL I . Secondary hyperparathyroidism of morbid obesity regresses during weight reduction. Metabolism. 1988; 37(5):425-8. DOI: 10.1016/0026-0495(88)90041-8. View

10.

Christiansen T, Richelsen B, Bruun J . Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int J Obes (Lond). 2004; 29(1):146-50. DOI: 10.1038/sj.ijo.0802839. View

11.

Bolland M, Grey A, Ames R, Horne A, Gamble G, Reid I . Fat mass is an important predictor of parathyroid hormone levels in postmenopausal women. Bone. 2005; 38(3):317-21. DOI: 10.1016/j.bone.2005.08.018. View

12.

Ricci T, Heymsfield S, Pierson Jr R, Stahl T, Chowdhury H, Shapses S . Moderate energy restriction increases bone resorption in obese postmenopausal women. Am J Clin Nutr. 2001; 73(2):347-52. DOI: 10.1093/ajcn/73.2.347. View

13.

Kim C, Park H, Kawada T, Kim J, Lim D, Hubbard N . Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes (Lond). 2006; 30(9):1347-55. DOI: 10.1038/sj.ijo.0803259. View

14.

Gunther C, Lyle R, Legowski P, James J, McCabe L, McCabe G . Fat oxidation and its relation to serum parathyroid hormone in young women enrolled in a 1-y dairy calcium intervention. Am J Clin Nutr. 2005; 82(6):1228-34. DOI: 10.1093/ajcn/82.6.1228. View

15.

Nakchbandi I, Mitnick M, Lang R, Gundberg C, Kinder B, Insogna K . Circulating levels of interleukin-6 soluble receptor predict rates of bone loss in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2002; 87(11):4946-51. DOI: 10.1210/jc.2001-011814. View

16.

Chang E, Donkin S, Teegarden D . Parathyroid hormone suppresses insulin signaling in adipocytes. Mol Cell Endocrinol. 2009; 307(1-2):77-82. PMC: 2714196. DOI: 10.1016/j.mce.2009.03.024. View

17.

Takahashi K, Mizuarai S, Araki H, Mashiko S, Ishihara A, Kanatani A . Adiposity elevates plasma MCP-1 levels leading to the increased CD11b-positive monocytes in mice. J Biol Chem. 2003; 278(47):46654-60. DOI: 10.1074/jbc.M309895200. View

18.

Hagstrom E, Hellman P, Larsson T, Ingelsson E, Berglund L, Sundstrom J . Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation. 2009; 119(21):2765-71. DOI: 10.1161/CIRCULATIONAHA.108.808733. View

19.

Duan Y, De Luca V, Seeman E . Parathyroid hormone deficiency and excess: similar effects on trabecular bone but differing effects on cortical bone. J Clin Endocrinol Metab. 1999; 84(2):718-22. DOI: 10.1210/jcem.84.2.5498. View

20.

Bilezikian J, Rubin M, Silverberg S . Asymptomatic primary hyperparathyroidism. Arq Bras Endocrinol Metabol. 2006; 50(4):647-56. DOI: 10.1590/s0004-27302006000400010. View